INTERNATIONAL SEARCH REPORT

11 1ational Application No PCT/GB 00/03760

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68 C07K14/415 A61P37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 - 601N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, CHEM ABS Data, BIOSIS, EMBASE, EPO-Internal, WPI Data, PAJ

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'KEEFFE J ET AL: "T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC)." CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 117, no. 2, August 1999 (1999-08), pages 269-276, XP000989621 ISSN: 0009-9104 the whole document	1-3, 6-12, 22-26,37
X ,	EP 0 905 518 A (UNIV LEIDEN ;ACADEMISCH ZIEKENHUIS LEIDEN (NL)) 31 March 1999 (1999-03-31) the whole document 	12, 14-22, 25-59

*	*
X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed 	 "T" tater document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 2 March 2001	Date of mailing of the international search report 28/03/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tet. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Gundlach, B

2

INTERNATIONAL SEARCH REPORT II. In Internation No

Ir. ational Application No PCT/GB 00/03760

Category °	Citation of document, with indication, where appropriate, of the relevant passages	. Relevant to claim No.
Category	Glasion of Occurrent, with indication, where appropriate, of the relevant passages	riolovani to ciamino,
Х	VAN DE WAL YVONNE ET AL: "Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin."	1-3, 6-12, 22-26,37
	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 17,	
	18 August 1998 (1998-08-18), pages 10050-10054, XP000982626 Aug. 18, 1998 ISSN: 0027-8424 the whole document	
X 2	TRONCONE R ET AL: "Cytokines produced by gliadin-specific T cell clones from the coeliac mucosa." GASTROENTEROLOGY, vol. 110, no. 4 SUPPL., April 1996 (1996-04), page A1031	1-3, 6-12, 22-26,37
	XP000989625 96th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week;San Francisco,	*
	California, USA; May 19-22, 1996 ISSN: 0016-5085 abstract	
X	GODKIN A J ET AL: "Identification of a coeliac disease-specific T cell epitope from A-gliadin." GUT, vol. 44, no. SUPPL. 1,	1-3, 6-12, 22-26,37
	April 1999 (1999-04), page A72 XP000989626 British Society of Gastroenterology Annual Meeting; Glasgow, Scotland, UK; March 23-25, 1999 ISSN: 0017-5749 abstract	
A	OKITA T W ET AL: "EVOLUTION AND HETEROGENEITY OF THE ALPHA-BETA-TYPE AND GAMMA-TYPE GLIADIN DNA SEQUENCES" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 260, no. 13, 1985, pages 8203-8213, XP000982597	38-59
	ISSN: 0021-9258 the whole document -& DATABASE SWISSPROT 'Online! ID: GDA4_Wheat ACC: P04724, 13 August 1987 (1987-08-13) XP002161985	*
	abstract -/	

2

INTERNATIONAL SEARCH REPORT

ii ational Application No
PCT/GB 00/03760

		101/48 00	/GB 00/03760		
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		Data and a second		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
х	UHLIG H ET AL: "Role of tissue transglutaminase in gliadin binding to reticular extracellular matrix and relation to coeliac disease autoantibodies." AUTOIMMUNITY, (1998) 28 (4) 185-95., XP002118954 page 186, left-hand column, paragraph 2	- ,	13		
Ρ,Χ	ANDERSON ROBERT P ET AL: "In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope." NATURE MEDICINE, vol. 6, no. 3, March 2000 (2000-03), pages 337-342, XP000982628 ISSN: 1078-8956 the whole document		1-34,37		
P,X	ARENTZ-HANSEN, HELENE ET AL: "The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase" J. EXP. MED., vol. 191, no. 4, 21 February 2000 (2000-02-21), pages 603-612, XP000986723 the whole document		1-34,37		
		·			
-					

International Application No. PCT&B 00 03760

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim(s) 5 and 40 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. And although claims 41 and 42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT — Method for treatment of the human or animal body by therapy Rule 39.1(iv) PCT — Diagnostic method practised on the human or animal body



INTER	TERNATIONAL SEARCH	H REPORT	. (
	Information on patent family member	rs		B 00/03760	
Patent document cited in search report	Publication date	Patent family member(s)	,	Publication date	
EP 0905518 A	31-03-1999	NONE	,		
					•
		·		·	
	·				
*					
	·				

THIS PAGE BLANK (USPTO)